CSL Seqirus to Present 14 Abstracts at ESWI 2025
CSL Seqirus, a leading influenza vaccine provider, announced today that it will present 14 abstracts at the European Scientific Working group on Influenza (ESWI) conference, taking place from 20–23 October in Valencia, Spain. The company’s participation underscores the vital role of enhanced seasonal influenza vaccines in protecting public health and advancing scientific understanding of influenza prevention.
Key Data Highlights and What They Mean for Public Health
The presentations cover a range of real-world and comparative effectiveness data. Highlights include a Public Health and Comparative Cost Analysis of Enhanced Influenza Vaccination in Adults Aged >65 years across Nordic regions and a study on comparative vaccine effectiveness of adjuvanted and high-dose influenza vaccines in preventing test-confirmed influenza outcomes, including hospitalisations, during the 2022–2024 seasons. Poster details and timings are as follows:
- Public Health and Comparative Cost Analysis of Enhanced Influenza Vaccination in Adults Aged >65 years Across the Nordic Regions — Poster 238, 21 October, 18:00–18:30
- Comparable Vaccine Effectiveness of Adjuvanted and High-Dose Influenza Vaccines in Preventing Test-Confirmed Influenza Outcomes — Poster 153, 22 October, 17:30–19:00
Speaking on the significance of the data, Jonathan Anderson, Executive Medical Director, International Regions (Europe and Asia Pacific) at CSL Seqirus, noted: “The data being presented at ESWI this year will highlight the clear effectiveness of enhanced seasonal influenza vaccines. These data show clearly the benefit enhanced influenza vaccines may have to public health.”
Leadership Voices on ESWI’s Importance
Pepe Meseguer Perez, Spain and Iberian Cluster Head at CSL Seqirus, described ESWI as a pivotal gathering for the vaccine community to exchange the latest infectious disease research. “ESWI’s 10th congress is underpinned by the strength of the data we have submitted, and we are excited to welcome the vaccine community to Valencia to share our results,” Perez said.
Supporting Next-Generation Scientists
CSL Seqirus backs the next generation of researchers through the 4th Young Scientist Vaccine Innovation Award. The ceremony is scheduled for 23 October, 09:30–10:30, recognizing outstanding early-career work in influenza vaccine development. In addition, a Satellite Symposium will be held on 21 October, 16:00–17:00, under the theme “Addressing the Evolving Influenza Landscape: A Public Health Imperative,” highlighting the evolving science and its implications for public health policy.
About Seasonal Influenza and the Vaccine Landscape
Seasonal influenza remains a significant global health burden, capable of causing mild to severe illness and, in some cases, death. Transmission can occur before symptoms appear and continue for several days after, making vaccination a key preventive measure. In Europe alone, seasonal influenza has been associated with thousands of deaths annually, underscoring the importance of effective vaccination strategies and ongoing research into enhanced vaccines.
About CSL Seqirus
CSL Seqirus is a leading influenza vaccine provider and a global partner in pandemic preparedness. With production facilities in the United States, the United Kingdom, and Australia, CSL Seqirus leverages egg, cell, and adjuvant technologies to offer a broad portfolio of vaccines in more than 20 countries. More information is available at CSL.com.
About CSL
CSL is a global biotechnology company (ASX: CSL) with a broad portfolio spanning medicines, vaccines—including influenza vaccines—and therapies for iron deficiency and nephrology. Since 1916, CSL has pursued life-saving innovations through the combined strengths of its business units: CSL Behring, CSL Seqirus, and CSL Vifor, serving patients in more than 100 countries.
Forward-Looking Statements and Safety Information
This release contains forward-looking statements about future results and events, which involve risks and uncertainties. Please refer to CSL’s regulatory filings for a discussion of these risks. For safety information about FLUAD® (Influenza Vaccine, Adjuvanted) and related products, consult the full prescribing information and speak with a healthcare provider.
Event Details and Access
For media and investors seeking more information about the ESWI 2025 presentations and CSL Seqirus’ broader influenza vaccine program, please contact the CSL Seqirus communications team.
